



Capturing heterogeneity and the HLA-presented landscape in melanoma

Yardena Samuels

Ph.D. Weizmann Institute of Science



Society for Immunotherapy of Cancer

#SITC2020



I have no conflict to disclose




Society for Immunotherapy of Cancer


#SITC2020

Tumor heterogeneity Vs. Mutational Load: current assumptions in immunotherapy

- Tumors with increased mutational are associated with checkpoint blockade sensitivity (*Rivzi et al, Science 2015 ; Van Ellen et al, Science 2015*)
- Low heterogeneity of the tumors is also associated with better response for checkpoint blockade (*McGranahan et al, Science 2016*)



Van Allen et al, Science 2015



McGranahan et al, Science 2016

However, mutational count cannot **predict** responsiveness
(Hugo et al, 2015)




Osnat Bartok

Tumor heterogeneity Vs. Mutational Load: Experimental system




Yochai Wolf

Tumor heterogeneity Vs. Mutational Load: Experimental system




Cell lines are injected into immunocompetent/ immunocompromised mice

Tumor growth in UVB irradiated cell line






Despite higher mutational count UVB irradiated cells gave rise to highly aggressive tumors

Tumor heterogeneity Vs. Mutational Load: Experimental system




UVB irradiated single cell clones are non aggressive




Wolf, Bartok, et al, *Cell* 179, 219-235, 2019

UVB irradiated single cell clones are non aggressive





Clonal structure and heterogeneity of UVB tumors remains stable *in vivo* over time




**The aggressive growth of the UVB tumor
is not due to an escaper clone**

The aggressive growth of the UVB tumor Is not due to an escaper clone





Wolf, Bartok, et al, *Cell* 179, 219-235, 2019


Reduced growth of low heterogeneous UVB clones is due to immune rejection



Reduced growth of low heterogeneous UVB clones is due to immune rejection




Efficient infiltration of T cells to tumor core in single cell derived tumors






Wolf, Bartok, et al, *Cell* 179, 219-235, 2019

Differential immune output in tumors with varying heterogeneity




Identification of neoantigens that mediate killing *in vivo*



Wolf, Bartok, et al, *Cell* 179, 219-235, 2019



Assessing the role of intra-tumor heterogeneity in tumor rejection-using phylogenetic tree reconstruction




Two fundamental components of tumor heterogeneity:

- The **number of clones** comprising the tumor
- The genetic **diversity** between them

Mixture of 6 clones from the same terminal branch was swiftly rejected




Mixture of 12 clones from the same terminal branch was swiftly rejected





Wolf, Bartok, *et al* & Samuels, *Cell* 179, 219-235, 2019


Mixes containing more clones and higher diversity were most aggressive



Although yielding large tumors, the 12AB tumors were still not as aggressive as the UVB-irradiated tumors




The **number of clones** and **their genetic diversity** play an important role in mediating tumor growth and rejection




Shannon diversity index: metric to quantify both the number of clones and the diversity of the mutations across clones in one index

Shannon diversity index low:




nearly all mutations are concentrated in just one clone

Shannon diversity index high:



high number of clones, with mutations spread evenly/diversely across each clone

Tumor clone number and genetic diversity are significantly associated with response to immunotherapy



*** $P_{\text{meta}} = 0.0105$

*P-value for SDI as a continuous variable, z-test from Cox PH model

**Hazard ratio, per unit increase in SDI

***Meta-analysis of p-values from Snyder, Riaz, Hugo and Van Allen cohorts

Hazard ratio value corresponding to the survival risk per unit increase (i.e. each +1 increment) in SDI.

Wolf, Bartok, et al, *Cell* 179, 219-235, 2019

Summary: our mouse, TCGA and ICT data are complimentary in suggesting that:

- Mutational load alone is not a sufficient predictor for immune response
- Intra-tumor heterogeneity has to be considered as an additional biomarker
- Intra-tumor heterogeneity is composed of both: **clonal diversity**
number of clones
- Minimizing tumor heterogeneity exposes reactive neo-antigens to better immune detection

The combination of these factors will strongly dictate the extent of the overall immune response and have strong clinical implications

Research Highlight | Published: 04 October 2019

TUMOUR IMMUNOLOGY

Tumour heterogeneity determines immune response

Alexandra F...

Nature Reviews

1532 Access

CellPress

Research Highlight | Published: 27 September 2019

SKIN CANCER

A need to quantify intra-tumor heterogeneity to improve patient selection for checkpoint blockade therapy

Tumor Neoantigens: When Too Much of a Good Thing Is Bad

Anne Trinh^{1,2} and Kornelia Polyak^{1,2,*}

¹Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA

²Department of Medicine, Harvard Medical School, Boston, MA 02115, USA

*Correspondence: kornelia_polyak@dfci.harvard.edu

<https://doi.org/10.1016/j.ccell.2019.10.009>

CANCER DISCOVERY


Search...

[Home](#) [About](#) [Articles](#) [For Authors](#) [Alerts](#) [News](#)


Research Watch

Low-Heterogeneity Melanomas Are More Immunogenic and Less Aggressive

Costimulatory and coinhibitory interactions determine the amplitude of T-cell activation



How do T cells recognize and kill tumor cells?




Kalaora *et al* & Samuels, *Oncotarget* 2015

Scheme kindly provided by Paul Robbins and Cyrille Cohen

HLA Peptidomics to Identify Human Immunogenic Neo-antigens




Shelly Kalaora



Proof of Concept: Neoantigen characterization in melanoma line 12T

Sequence	Protein name	Mutation	HLA allele
DANSFLQSV	MED15	P677S	B*51
KLFEDRVGTIK	TPD52L2	S123L	A*03
GVYPMPGTQK	NCAPH2	S174Y	A*03



Kalaora et al, *Cancer Discovery* 8, 1366-1375, 2018

Identification of bacteria-derived HLA-presented peptides

Identification of intra-tumor bacteria

Research

GENOME
RESEARCH 2012

Genomic analysis identifies association of *Fusobacterium* with colorectal carcinoma

Aleksandar D. Kostic.^{1,2} Dirk Gevers.¹ Chandra Sekhar Pedomallu.^{1,3} Monia Michaud.⁴
Fujiko Du [OPEN ACCESS Freely available online](#)

PLOS ONE

2014

However

It has never been shown whether tumor HLA class I and HLA class II molecules can present microbial antigens

Noam Shental,⁸ Deborah Nejman,¹ Zachary A. Cooper,^{7,8} Kevin Shee,² Jonathan Livny,² Roi Avraham,¹⁰ D. Kelly Chatman,¹² Stephen E. Johnston,¹² Garold Fuks,¹² Candice Gurbatri,¹⁰ Mark W. Hurd,¹⁷ Matthew Katz,⁸ Ji Matt Skalak,⁷ Jeffrey Bu,⁸ Monia Michaud,⁴ Talia Golan,^{21,22} Judith Sandbank,² Wendy S. Garrett,^{2,10,24} Sarah P. Th Curtis Huttenhower,^{2,27} Sangeeta N. Wargo,^{7,8} Todd R. Golub

CANCER

The human tumor microbiome is composed of tumor type-specific intracellular bacteria

Deborah Nejman^{1*}, Ilana Livyatan^{1,2*}, Garold Fuks^{3*}, Nancy Gavert¹, Yaara Zwang¹, Leore T. Geller¹, Aviva Rotter-Maskowitz¹, Roi Weiser^{4,5}, Giuseppe Mallei¹, Elinor Gigi¹, Arnon Meltzer¹, Gavin M. Douglas⁶, Iris Kamer⁷, Vancheswaran Gopalakrishnan⁸; Tali Dadosh⁹, Smadar Levin-Zaidman⁹, Sofia Avnet¹⁰, Tehila Atian¹¹, Zachary A. Cooper¹², Reetakshi Arora², Alexandria P. Cogdill¹³, Md Abdul Wadud Khan⁸, Gabriel Ologun⁸, Yuval Bussis^{1,2,14}, Adina Weinberger^{1,2}, Maya Lotan-Pompan^{1,2}, Ofra Golan¹⁵, Gili Perry¹⁶, Merav Rokah¹⁷, Keren Bahar-Shany¹⁸, Elisa A. Rozeman¹⁸, Christian U. Blank¹⁸, Anat Ronai¹⁹, Ron Shaoul¹⁹, Amnon Amit^{20,21}, Tatiana Dorfman^{22,23}, Ran Kremer²⁴, Zvi R. Cohen^{5,25}, Sagi Harnof^{5,26}, Tali Siegal²⁷, Einav Yehuda-Shnaidman²⁸, Einav Nili Gal-Yam²⁹, Hagit Shapira²⁸, Nicola Baldini^{30,30}, Morgan G. I. Langille^{6,31}, Alon Ben-Nun^{3,37}, Bella Kaufman^{3,7}, Aviram Nissan³², Talia Golan^{5,7}, Maya Dadiani³³, Keren Levanon^{3,16}, Jair Bar^{3,7}, Shlomit Yust-Katz^{5,27}, Iris Barshack^{5,33}, Daniel S. Peeper³⁴, Dan J. Raz³⁵, Eran Segal^{1,2}, Jennifer A. Wargo^{8,13}, Judith Sandbank²⁸, Noam Shental³⁶†, Ravid Straussman¹†§

Science 2020




Shelly Kalaora

Pipeline for the identification of intra-tumor Bacterial antigens



Adi Nagler




Short talk to be given by Adi Nagler
 Concurrent Session 108: Diet and Microbiome
 11/11/2020, 3:45 pm

Jennifer Wargo
 Ravid Straussman
 Deborah Rosenberg

Kalaora, Nagler et al & Samuels, *Nature*, *In Revision*


Phylogenetic tree of all bacteria that were identified in the tumors using 16s rDNA



Class	Order	Genus
Bacilli	Bacillales Lactobacillales	Staphylococcus Streptococcus
Bacteroidia	Bacteroidales	Bacteroides Prevotella Porphyromonas
Epsilonproteobacteria	Campylobacterales	Campylobacter
Clostridia	Clostridiales	Clostridium Veillonella Dialister
Betaproteobacteria	Neisseriales	Eikenella Kingella
Fusobacteriia	Fusobacteriales	Fusobacterium Leptotrichia
Gamma proteobacteria	Vibrionales Enterobacteriales Alteromonadales Pseudomonadales	Photobacterium Klebsiella Shewanella Enterobacter Acinetobacter
Actinobacteria	Actinomycetales Micrococcales Bifidobacteriales	Actinomyces Schaalia Corynebacterium Brachybacterium Gardnerella
Alphaproteobacteria	Rhodobacterales Sphingomonadales	Paracoccus Sphingomonas
Negativicutes	Veillonellales Selenomonadales	Dialister Selenomonas

Patients and metastases											
19	42	51	55	70	86	92	112	152			
19T	42RF	27	55A3	70.1	86B	92B3	112	152A2			
	42RB	51AL	55A7		86B2						
		51BR	55B3								

Bacterial peptides presented on HLA-I and HLA-II in each patient




Recurrent HLA class-I presented bacterial peptides

[illegible]


Kalaora, Nagler et al & Samuels, *Nature*, *In Revision*- please do not post

“Hot spot” HLA - presented bacterial peptides


Translation elongation factor EF-1 subunit alpha, *Enterobacter hormaechei*, HLA-II



Tr-type G domain-containing protein, *Enterobacter hormaechei*, HLA-II



Immunogenicity of bacterial peptides




Kalaora, Nagler et al & Samuels, *Nature*, *In Revision*- please do not post

Summary

- HLA peptidomics revealed bacterial antigens bound to HLA class I and class II in melanoma tumors
- The identified antigens are derived from bacteria that enter the melanoma cells, some are recurrent and some are immuno-reactive

**Identification of IFN γ -Induced ribosomal
frame-shifting
and HLA-presentation of aberrant
peptides**

The interferon gamma (IFN) response



We still don't completely understanding of the role of IDO1 and the consequences of Tryptophan degradation on cancer progression


Riboseq and mRNAseq from three melanoma cell lines exposed to IFN γ



Osnat Bartok

108T
12T
MD55A3

→ +/- 48h IFN γ




Tranlatome

Transcriptome

Noam Stern-Ginossar

Brar GA and Weissman JS, *Nat. Rev. Mol. Cell Biol.*, 2015.


IDO1 induction results in Trp to Kyn conversion






Bartok et al & Samuels*, Agami*, *Nature*, *In Revision*- please do not post

Effects on mRNA translation (initiation)

Analysis of Ribosome Protected Fragments (RPF) by DIRICORE (Differential Ribosome COdon REading)



IFN treatment



Global rate of translation


Metagene RPF distribution analysis of all expressed genes

Reuven Agami

Analysis of RPFs at position 15 demonstrates ribosome pausing on Tryptophan codons

Analysis of Ribosome Protected Fragments (RPF) by DIRICORE (Differential Ribosome COdon REading)


Analysis of RPFs by DIRICORE (Differential Ribosome COdon REading)




Bartok et al & Samuels*, Agami*, *Nature*, *In Revision*- please do not post

Effects on mRNA translation (elongation)

Analysis of RPFs by DIRICORE (Differential Ribosome COdon REading)





IFN vs Ctrl pos. 15





A strong accumulation of RPFs *downstream* of Trp- 'W Bumps'



Effects of IDO1 inhibition (IDOi)



**Position-specific
codon enrichment
analysis**




Summary so far . . .



**Why bumps at ~15 amino acids after Trp
codons?**

Disorderedness created by frameshifting



J. Mol. Biol. (1992) **223**, 31–40

Leftward Ribosome Frameshifting at a Hungry Codon

Jonathan A. Gallant and Dale Lindsley

*Department of Genetics SK-50
University of Washington, Seattle, WA 98195, U.S.A.*

(Received 22 May 1991; accepted 3 September 1991)

Vol. 187, No. 12

ting at the Tandem
AGA_AGA


Olga L. Gurvich,¹ Pavel V. Baranov,^{1,2} Raymond F. Gesteland,¹ and John F. Atkins^{1,2*}

Department of Human Genetics, University of Utah, 15N 2030E, Rm. 7410, Salt Lake City, Utah 84112-5330,¹ and Bioscience Institute, University College Cork, Cork, Ireland²

Received 2 December 2004/Accepted 4 March 2005



F0 AG
F+1 S A

Lentiviral Reporter System For The Identification of IFN γ -Induced Ribosomal Frame-Shifting




Bartok et al & Samuels*, Agami*, *Nature*, *In Revision*- please do not post

Lentiviral Reporter System For The Identification of IFN γ -Induced Ribosomal Frame-Shifting



IDOi abolishes IFN γ -induced frameshifting


Lentiviral Reporter System For The Identification of IFN γ -Induced Ribosomal Frame-Shifting



Lentiviral Reporter System For The Identification of IFN γ -Induced Ribosomal Frame-Shifting

888-Mel-
IFN γ **resistant**,
MART1⁺ melanoma cells



D10 -
IFN γ -**sensitive**,
MART1⁺ melanoma cells




Lentiviral Reporter System For The Identification of IFN γ -Induced Ribosomal Frame-Shifting

888-Mel-
IFN γ resistant,
MART1⁺ melanoma cells

D10 -
IFN γ -sensitive,
MART1⁺ melanoma cells







The weaker IDO1 induction in 888-Mel by IFN γ signaling is the likely cause of the lower frameshifting rate.




Lentiviral Reporter System For The Identification of IFN γ -Induced Ribosomal Frame-Shifting

888-Mel-
IFN γ resistant,
MART1⁺ melanoma cells

D10 -
IFN γ -sensitive,
MART1⁺ melanoma cells




Frame-shifted polypeptides observed using deep proteomics



IFN γ treatment induced a strong expression
Allowing the detection of frameshifted peptides

Frame-shifted data base:
predicted out-of-frame -1 and +1 polypeptides created by frameshifting at endogenous tryptophans of proteins expressed in MD55A3 cells, as determined by ribosome profiling



Endogenous production of *trans-frame* proteins and their presentation at on the cell surface

Gene	Sequence	Found in sample
KCNK6	VPLS LA EHAL	IFN γ
DBNDD2	S PLSSLSTL	IFN γ
DIP2B	QFLAEILQ V	IFN γ
AC129492.1	S PTLSQCSL	IFN γ
HSP90AB1	M VSPLAGVPK	mTRP
ZNF513	V GQEGLVSL	mTRP
STK25	S PALRTLTL	IFN γ ,mTRP
FCGBP	A PSGVAAGL	IFN γ ,mets
ESPNL	LFLSH LEE I	IFN γ ,mets
RPL7A	V AAAESHPL	IFN γ ,mets
TRAM1L1	T SLVNLSTL	mTRP,mets
GEMIN5	S PRGPPSSL	IFN γ ,mTRP,mets

-1
+1

V P L S W
GUG CCC CUG UCU **UGG** CUG AGC AUG CGU UGG

L A E H A L

Aberrant: VPLS**LA**EHAL Canonical: VPLSWLSMRW

V L G R W
GUU CUU GGA CGU **UGG** GGC AAC UAC AGC UCU G


G A T T A L

Aberrant: VLGR**G**ATTAL Canonical: VLGRWGNYS


Endogenous production of *trans-frame* proteins and their presentation at on the cell surface

Gene	Sequence	Found in sample
KCNK6	VPLS LA EHAL	IFN γ
DBNDD2	SPL SSLSTL	IFN γ
DIP2B	QFLAEILQ V	IFN γ
AC129492.1	SPTLS QC SL	IFN γ
HSP90AB1	MV SPLAGVPK	mTRP
ZNF513	VGQ EGLVSL	mTRP
STK25	SPAL RTLTL	IFN γ ,mTRP
FCGBP	APSG VAGL	IFN γ ,mets
ESPNL	LFLSH LEE I	IFN γ ,mets
RPL7A	VAAA ESHPL	IFN γ ,mets
TRAM1L1	TSL VNLSTL	mTRP,mets
GEMIN5	SPRG PPSSL	IFN γ ,mTRP,mets

-1
+1




Aberrant: VPLS**LA**EHAL Canonical: VPLSWLSMRW



Aberrant: VLGR**G**ATTAL Canonical: VLGRWGNYS

Identification of reactive T cells to tryptophan-derived aberrant peptides


Tetramer screening of B07:02/C07:02 co-culture at Day 10 (D#18)



KCNK6 peptide specific T cell population (0.05%) was detected in one well of D#18 T cells. This population was single cell sorted onto feeders for T cell cloning and further validation


Identification of reactive T cells to tryptophan-derived aberrant peptides

16 out of 180 single cell sorted T cells from KCNK6 tetramer positive population grew out on feeders.




All 13 tetramer positive KCNK6 T cell clones reacted positively with KCNK6 peptide loaded K562-B07:02 cells.
Clone #4 that was tetramer negative did not react.


Summary



New layer of intra-tumor heterogeneity: on the HLA-presentation level



New layer of intra-tumor heterogeneity: on the HLA-presentation level



The Samuels Lab



Acknowledgments

Samuels Lab

Osnat Bartok
Yochai Wolf (alumnus)
Sapir Cohen
Ronen Levy
Gitit Bar Eli (alumnus)
Shelly Kalaora
Adi Nagler
Michal Alon
Polina Greenberg
Aviyah Peri
Tal Alter
Eden Goldfarb
Nofar Amsalem
Deborah Hayoun
Chaya Barbolin
Alexandra Gurman

NCI NIH

Eytan Ruppin
Joo Sang Lee
Sushant Patkar
Glenn Merlino
Chi-Ping Day

Francis Crick Institute

Charles Swanton
Kevin Litchfield

JHU

David Sidransky

Hadassah

Michal Lotem
Eli Pikarsky, Ilan Stein
Einat Cinnamon

Weizmann Institute

Ravid Straussman
Deborah Rosenberg
Nir Friedman
Dan Reshef
Erez Greenstein
Lea Eisenbach
Noam Stern-Ginossar
Orel Mizrahi
Roni Oren
Alexander Brandis
Yishai Levin
Technion
Arie Admon
Eilon Barnea
Shai Shen Orr

NKI

Reuven Agami
Abhijeet
Pataskan
Remco Nagel
Daniel Peeper

MD Anderson

Jennifer Wargo

University of Oslo

Johanna Olweus
Maarja Laos

University of Zürich

Reinhard Dummer
Mitch Levesque



FUNDACIÓN
RAMÓN ARECES